Inhibitory effects of Δ8-tetrahydrocannabinol on nicotine metabolism and implications as a smoking cessation agent
Open Access
- 13 January 2026
- journal article
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 54 (3) , 100235
Abstract
No abstract availableKeywords
Funding Information
- National Cancer Institute
- National Cancer Institute Division of Cancer Prevention (7R01CA269223)
This publication has 56 references indexed in Scilit:
- Identification of human hepatic UDP-glucuronosyltransferases involved in the glucuronidation of temazepamDrug Metabolism and Disposition, 2025
- CYP2C9, CYP3A and CYP2C19 metabolize Δ9-tetrahydrocannabinol to multiple metabolites but metabolism is affected by human liver fatty acid binding protein (FABP1)Biochemical Pharmacology, 2024
- Adolescent Δ8-THC and Marijuana Use in the USJAMA, 2024
- Evaluation of Cytochrome P450‐Mediated Cannabinoid‐Drug Interactions in Healthy Adult ParticipantsClinical Pharmacology & Therapeutics, 2023
- New medications development for smoking cessationAddiction Neuroscience, 2023
- Do Inhibitory Metabolites Impact DDI Risk Assessment? Analysis of in vitro and in vivo Data from NDA Reviews Between 2013 and 2018Clinical Pharmacology & Therapeutics, 2021
- Worldwide Distribution of Cytochrome P450 Alleles: A Meta‐analysis of Population‐scale Sequencing ProjectsClinical Pharmacology & Therapeutics, 2017
- Cannabidiol reduces cigarette consumption in tobacco smokers: Preliminary findingsAddictive Behaviors, 2013
- Nicotine Chemistry, Metabolism, Kinetics and Biomarkers2009
- CYP2A6 genotype and the metabolism and disposition kinetics of nicotineClinical Pharmacology & Therapeutics, 2006